Anika Therapeutics (ANIK) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
28 Apr, 2026Voting matters and shareholder proposals
Election of three Class III Directors: Gary P. Fischetti, John B. Henneman III, and Stephen D. Griffin, all recommended by the board.
Ratification of Deloitte & Touche LLP as independent registered accounting firm for fiscal year ending December 31, 2026.
Advisory vote on executive compensation (say-on-pay) is included.
Approval sought for amendments to the 2017 Omnibus Incentive Plan and the 2021 Employee Stock Purchase Plan.
Other business may be addressed as appropriate at the meeting or any adjournment.
Board of directors and corporate governance
Board recommends all director nominees for election to Class III positions.
Executive compensation and say-on-pay
Advisory vote on named executive officer compensation is on the agenda.
Amendments to incentive and employee stock purchase plans are proposed for approval.
Latest events from Anika Therapeutics
- Q2 2026 saw 16% revenue growth, 65% gross margin, and raised full-year guidance.ANIK
Q2 2026 - All proposals passed by majority vote, with no questions from stockholders.ANIK
AGM 2026 - Revised equity plan lowers dilution, aligns with governance best practices, and seeks shareholder approval.ANIK
Proxy filing - Shareholders are asked to approve a clarified, board-backed incentive plan amid dilution concerns.ANIK
Proxy filing - Revenue up 13% with margin expansion and strong adjusted EBITDA; guidance reaffirmed.ANIK
Q1 2026 - Shareholders to vote on director elections, auditor, compensation, and equity plan amendments.ANIK
Proxy filing - HA-based innovation and commercial growth fuel market expansion and a positive outlook through 2027.ANIK
2026 CG Musculoskeletal Conference - 2026 revenue is guided up 1–9%, led by double-digit commercial channel growth and operational gains.ANIK
Q4 2025 - Expanding regenerative portfolio and U.S. launches drive growth amid strategic refocus.ANIK
Piper Sandler 36th Annual Healthcare Conference